Media.Player

Diazene-Bridge Crown Ether Lithium Compounds And Methods For Their Use

Summary

This Invention Provides A Method For Treating An Eye Disease In A Patient Comprising: Providing A Photosensitive Prodrug That Releases Upon Exposure To Light An Active Ingredient To Treat The Eye Disease; Administering The Prodrug In A Pharmaceutically Accepted Vehicle To The Subject, And Exposing The Eye Of The Subject To An External Light Source To Cause The Prodrug To Release The Active Ingredient. This Invention Also Provides A Composition For The Treatment Of Glaucoma, Comprising A Compound Containing A Lithium Ion-Chelated In A Crown Ether- Or Aza-Crown Ether-Containing Chromene Or Diazene Derivative And A Pharmaceutically Acceptable Carrier.

Supplementary Information

Patent Number: US7468434B2
Application Number: US2005313513A
Inventor: Vanhoutte, Paul Michel Georges | Che, Chi-Ming | So, Kwok-Fai | Sham, Iona Hiu Tung
Priority Date: 22 Dec 2004
Priority Number: US7468434B2
Application Date: 21 Dec 2005
Publication Date: 23 Dec 2008
IPC Current: C07D022500
US Class: 540450 | 540467 | 540468 | 540469
Assignee Applicant: The University of Hong Kong
Title: Diazene-bridge crown ether lithium compounds and methods for their use
Usefulness: Diazene-bridge crown ether lithium compounds and methods for their use
Summary: For protecting degeneration of retinal ganglion cells in individual, where the degeneration is caused by eye disease e.g. glaucoma (claimed).
Novelty: Use of photosensitive prodrug that releases active ingredient upon exposure to light, for protecting degeneration of retinal ganglion cells in the treatment of eye disease e.g. glaucoma

Industry

Chemical/Material

Sub Category

Chemical/Material Application

Application No.

US2005313513A

Country/Region

Hong Kong